Related Experiment Video
Updated: Jun 16, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
'Image and treat': an individualized approach to urological tumors
Kirsten Bouchelouche1, Jacek Capala
1PET and Cyclotron Unit, PET 3982 Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. bouchelouche@mail.tele.dk
Purpose Of Review:
The current treatment options for advanced urologic cancers demonstrate limited efficacy. To obtain optimal clinical results, there is a need for new, individualized, therapeutic strategies, which have only recently been applied to these malignancies. Nuclear medicine plays an important role in establishing imaging biomarkers necessary for personalized medicine. This review focuses on the current status of the 'image and treat' approach combining molecular imaging with targeted radionuclide therapy of urological malignancies
Recent Findings:
Tumor-specific targets in uro-oncology are showing promising results for development of personalized therapy using positron emission tomography/computed tomography (PET/CT) molecular imaging and radioimmunotherapy. The antibody cG250, which binds to carbonic anhydrase IX, is being evaluated as a radiolabeled imaging and therapeutic agent in clear-cell renal cell carcinoma. I-cG250 PET/CT has demonstrated excellent targeting of clear-cell renal cell carcinoma. Prostate-specific membrane antigen is a promising target for both PET/CT and radioimmunotherapy of prostate cancer. HER2 may be another potential target in bladder and prostate cancer.
Summary:
Tumor-specific targets and biomarkers are being studied for PET/CT and radioimmunotherapy. This may lead to development of new therapeutic strategies. However, considerable investment in new research will be required for personalized medicine to be routinely used in uro-oncology.
Insights
Personalized nuclear medicine, combining molecular imaging and targeted radionuclide therapy, offers new hope for advanced urologic cancers. This
Area of Science:
- Uro-oncology
- Nuclear Medicine
- Personalized Medicine
Background:
- Current treatments for advanced urologic cancers have limited efficacy.
- Individualized therapeutic strategies are emerging for these malignancies.
- Nuclear medicine provides essential imaging biomarkers for personalized medicine.
Purpose of the Study:
- To review the 'image and treat' approach for urological malignancies.
- Focus on combining molecular imaging with targeted radionuclide therapy.
- Highlight the role of nuclear medicine in personalized urologic oncology.
Main Methods:
- Review of current literature on molecular imaging and radionuclide therapy in urologic cancers.
- Evaluation of tumor-specific targets for imaging and therapy.
- Analysis of positron emission tomography/computed tomography (PET/CT) applications.
Main Results:
- Tumor-specific targets like carbonic anhydrase IX (cG250) and prostate-specific membrane antigen (PSMA) show promise.
- Radioiodinated cG250 (I-cG250) PET/CT demonstrates effective targeting in clear-cell renal cell carcinoma.
- PSMA is a viable target for PET/CT and radioimmunotherapy in prostate cancer; HER2 is a potential target for bladder and prostate cancer.
Conclusions:
- Tumor-specific targets and biomarkers are under investigation for advanced PET/CT and radioimmunotherapy applications.
- Development of novel therapeutic strategies is anticipated.
- Significant research investment is necessary for routine clinical implementation of personalized medicine in uro-oncology.
Related Concept Videos
Imaging Studies I: Kidney, Ureter, and Bladder Studies
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Urinary Tract Calculi VI: Surgical Management
Imaging Studies IV: Magnetic Resonance Imaging
Imaging Studies III: Computed Tomography

